Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

These data were created on 15th July of 2015 for the paper to be published in Advanced Materials. We have developed a new formulation of volatile nanodroplets, stabilised by a protein and polymer coating. The nanodroplets are prepared from hydrophobic perfluoropentane (PFP) and coated with human serum albumin and polyethylene glycol modified N-hydrosuccinimide conjugated in dichloromethane using an oil-in-water emulsification method. The resulting nanodroplets have an average diameter of 344 nm and are stable at 37oC for several days. These properties offer advantages both for storage of the droplets and their ability to extravasate and permeate target tissue as compared with microbubble agents. Upon exposure to ultrasound the nanodroplets undergo a phase change, generating microbubbles. The efficiency of this process was increased by a factor of 2.8 when iron oxide nanocrystals were added to the PFP. In addition, hydrophobic drugs can be incorporated into the droplet core and the release characteristics of an anti-cancer drug, paclitaxel, were studied. The rate of drug release was found to increase by 70.7 % compared to a control formulation without PFP upon exposure to ultrasound for 180 seconds. Finally the effect of the nanodroplets on breast cancer cells was compared with that of the control formulation, and it was found that the droplets showed 38%p enhanced cytotoxicity than that of free drug.

Original publication






University of Oxford

Publication Date



nanodroplets, chemotherapy, microbubbles, breast cancer, ultrasound